Perspective Therapeutics (CATX) said Friday it has dosed the first patient in a new cohort of its phase 1/2a trial evaluating [212Pb]VMT01 as a monotherapy for melanoma patients with confirmed positive MC1R imaging scans.
This cohort includes patients with brain metastases and administers [212Pb]VMT01 at a dose of 1.5 millicuries.
The investigational therapy delivers targeted alpha-particle therapy to treat metastatic melanoma. The US Food and Drug Administration granted Fast Track Designation for [212Pb]VMT01 in September 2024.
Perspective Therapeutics shares were up over 17% in recent premarket activity.
Price: 2.19, Change: +0.33, Percent Change: +17.74
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。